JMP Securities Maintains Market Outperform on Structure Therapeutics, Raises Price Target to $91
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has maintained a Market Outperform rating on Structure Therapeutics and increased the price target from $90 to $91. The company is listed on NASDAQ under the ticker GPCR.
November 15, 2023 | 5:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Structure Therapeutics' stock may see a positive impact in the short term due to JMP Securities' analyst rating maintenance and price target increase from $90 to $91.
Analyst ratings and price target adjustments are significant indicators for investors. The increase in price target by JMP Securities suggests a positive outlook for Structure Therapeutics, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100